Effects of Acarbose combined with Metformin in treatment of obese patients with type 2 diabetes mellitus
Objective:To observe effects of Acarbose combined with Metformin in treatment of obese patients with type 2 diabetes mellitus(T2DM).Methods:A prospective study was conducted on 82 obese T2DM patients admitted to the hospital from March 2020 to February 2023.According to the random number table method,they were divided into study group and control group,41 cases in each group.The control group was treated with Metformin hydrochloride tablets,while the study group was combined with Acarbose tablets on the basis of that of the control group.The clinical efficacy,the levels of glucose and lipid metabolism indexes[fasting blood glucose(FPG),2 h postprandial blood glucose(2hPG),low density lipoprotein cholesterol(LDL-C),triglyceride(TG)],insulin resistance indexes[fasting insulin(FINS),insulin resistance index(HOMA-IR)]and serum inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 95.12%(39/41),which was higher than 78.05%(32/41)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FPG,2hPG,TG,LDL-C,FINS,HOMA-IR,CRP and IL-6 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Acarbose combined with Metformin in the treatment of the obese T2DM patients can improve the total effective rate of treatment,reduce the levels of blood glucose,blood lipid and inflammatory factors,and reduce the insulin resistance.Moreover,it is superior to single Metformin treatment.
AcarboseMetforminObesity typeType 2 diabetes mellitusGlucose and lipid metabolismInsulin resistanceMicroinflammatory state
NETL
NSTL
万方数据
